Tactile Systems Technology I (TCMD)

$12.385

-0.44

(-3.39%)▲

Live

Insights on Tactile Systems Technology I

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 77.65M → 61.08M (in $), with an average decrease of 21.3% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 3 quarters, 22.29M → -2.20M (in $), with an average decrease of 95.1% per quarter

  • Vs BSX

    In the last 1 year, Boston Scientific Corp. has given 45.7% return, outperforming this stock by 90.5%

  • Vs BSX

    In the last 3 years, Boston Scientific Corp. has given 79.6% return, outperforming this stock by 154.0%

Performance

  • $12.34
    $12.85
    $12.39
    downward going graph

    0.4%

    Downside

    Day's Volatility :3.96%

    Upside

    3.58%

    downward going graph
  • $9.70
    $26.11
    $12.39
    downward going graph

    21.71%

    Downside

    52 Weeks Volatility :62.85%

    Upside

    52.55%

    downward going graph

Returns

PeriodTactile Systems Technology ISector (Health Care)Index (Russel 2000)
3 Months
-16.26%
-1.0%
0.0%
6 Months
-6.29%
9.6%
0.0%
1 Year
-46.34%
11.0%
0.0%
3 Years
-74.37%
18.5%
-22.6%

Highlights

Market Capitalization
306.5M
Book Value
$8.14
Earnings Per Share (EPS)
1.23
PE Ratio
10.49
PEG Ratio
17.24
Wall Street Target Price
20.67
Profit Margin
10.19%
Operating Margin TTM
-4.85%
Return On Assets TTM
3.6%
Return On Equity TTM
16.13%
Revenue TTM
276.7M
Revenue Per Share TTM
11.76
Quarterly Revenue Growth YOY
3.8%
Gross Profit TTM
176.0M
EBITDA
22.3M
Diluted Eps TTM
1.23
Quarterly Earnings Growth YOY
0.55
EPS Estimate Current Year
0.57
EPS Estimate Next Year
0.88
EPS Estimate Current Quarter
-0.11
EPS Estimate Next Quarter
0.11

Analyst Recommendation

Buy
    90%Buy
    10%Hold
    0
    0%Sell
Based on 10 Wall street analysts offering stock ratings for Tactile Systems Technology I(by analysts ranked 0 to 5 stars)
Based on 10 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
9
9
9
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 66.9%

Current $12.39
Target $20.67

Company Financials

FY18Y/Y Change
Revenue
143.8M
↑ 31.54%
Net Income
6.6M
↑ 13.12%
Net Profit Margin
4.61%
↓ 0.75%
FY19Y/Y Change
Revenue
189.5M
↑ 31.82%
Net Income
11.0M
↑ 65.65%
Net Profit Margin
5.79%
↑ 1.18%
FY20Y/Y Change
Revenue
187.1M
↓ 1.25%
Net Income
-620.0K
↓ 105.65%
Net Profit Margin
-0.33%
↓ 6.12%
FY21Y/Y Change
Revenue
208.1M
↑ 11.18%
Net Income
-11.8M
↑ 1805.0%
Net Profit Margin
-5.68%
↓ 5.35%
FY22Y/Y Change
Revenue
246.8M
↑ 18.61%
Net Income
-17.9M
↑ 51.27%
Net Profit Margin
-7.24%
↓ 1.56%
FY23Y/Y Change
Revenue
274.4M
↑ 11.2%
Net Income
28.5M
↓ 259.6%
Net Profit Margin
10.39%
↑ 17.63%
Q4 FY22Q/Q Change
Revenue
73.9M
↑ 13.24%
Net Income
4.6M
↓ 302.76%
Net Profit Margin
6.25%
↑ 9.74%
Q1 FY23Q/Q Change
Revenue
58.8M
↓ 20.37%
Net Income
-1.9M
↓ 140.81%
Net Profit Margin
-3.2%
↓ 9.45%
Q2 FY23Q/Q Change
Revenue
68.3M
↑ 16.13%
Net Income
-100.0K
↓ 94.7%
Net Profit Margin
-0.15%
↑ 3.05%
Q3 FY23Q/Q Change
Revenue
69.6M
↑ 1.82%
Net Income
22.3M
↓ 22399.0%
Net Profit Margin
32.05%
↑ 32.2%
Q4 FY23Q/Q Change
Revenue
77.7M
↑ 11.59%
Net Income
8.2M
↓ 63.22%
Net Profit Margin
10.56%
↓ 21.49%
Q1 FY24Q/Q Change
Revenue
61.1M
↓ 21.33%
Net Income
-2.2M
↓ 126.93%
Net Profit Margin
-3.62%
↓ 14.18%
FY18Y/Y Change
Total Assets
107.1M
↑ 21.06%
Total Liabilities
17.8M
↑ 13.67%
FY19Y/Y Change
Total Assets
151.8M
↑ 41.73%
Total Liabilities
39.2M
↑ 119.97%
FY20Y/Y Change
Total Assets
174.1M
↑ 14.72%
Total Liabilities
49.3M
↑ 26.0%
FY21Y/Y Change
Total Assets
244.3M
↑ 40.31%
Total Liabilities
116.0M
↑ 135.2%
FY22Y/Y Change
Total Assets
255.0M
↑ 4.39%
Total Liabilities
133.6M
↑ 15.13%
FY23Y/Y Change
Total Assets
281.4M
↑ 10.37%
Total Liabilities
87.8M
↓ 34.28%
Q4 FY22Q/Q Change
Total Assets
255.0M
↑ 2.6%
Total Liabilities
133.6M
↓ 0.4%
Q1 FY23Q/Q Change
Total Assets
275.5M
↑ 8.04%
Total Liabilities
119.3M
↓ 10.67%
Q2 FY23Q/Q Change
Total Assets
273.7M
↓ 0.64%
Total Liabilities
115.0M
↓ 3.67%
Q3 FY23Q/Q Change
Total Assets
293.3M
↑ 7.15%
Total Liabilities
110.5M
↓ 3.9%
Q4 FY23Q/Q Change
Total Assets
281.4M
↓ 4.05%
Total Liabilities
87.8M
↓ 20.53%
Q1 FY24Q/Q Change
Total Assets
272.0M
↓ 3.34%
Total Liabilities
78.6M
↓ 10.51%
FY18Y/Y Change
Operating Cash Flow
9.0M
↑ 114.86%
Investing Cash Flow
-14.7M
↑ 5.07%
Financing Cash Flow
1.9M
↓ 40.15%
FY19Y/Y Change
Operating Cash Flow
2.5M
↓ 72.13%
Investing Cash Flow
-2.3M
↓ 84.14%
Financing Cash Flow
2.5M
↑ 34.92%
FY20Y/Y Change
Operating Cash Flow
2.8M
↑ 11.31%
Investing Cash Flow
20.2M
↓ 964.2%
Financing Cash Flow
2.1M
↓ 15.38%
FY21Y/Y Change
Operating Cash Flow
2.6M
↓ 5.83%
Investing Cash Flow
-82.2M
↓ 507.27%
Financing Cash Flow
59.9M
↑ 2737.45%
FY22Y/Y Change
Operating Cash Flow
5.2M
↑ 97.99%
Investing Cash Flow
-1.9M
↓ 97.68%
Financing Cash Flow
-9.6M
↓ 116.02%
Q4 FY22Q/Q Change
Operating Cash Flow
3.9M
↑ 71.03%
Investing Cash Flow
-65.0K
↓ 95.45%
Financing Cash Flow
-5.3M
↑ 604.93%
Q1 FY23Q/Q Change
Operating Cash Flow
-502.0K
↓ 113.02%
Investing Cash Flow
-291.0K
↑ 347.69%
Financing Cash Flow
33.9M
↓ 740.72%
Q2 FY23Q/Q Change
Operating Cash Flow
13.9M
↓ 2870.72%
Investing Cash Flow
-851.0K
↑ 192.44%
Financing Cash Flow
-4.9M
↓ 114.34%

Technicals Summary

Sell

Neutral

Buy

Tactile Systems Technology I is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Tactile Systems Technology I
Tactile Systems Technology I
-9.65%
-6.29%
-46.34%
-74.37%
-74.91%
Stryker Corporation
Stryker Corporation
4.27%
16.65%
22.1%
34.77%
82.03%
Boston Scientific Corp.
Boston Scientific Corp.
4.07%
37.85%
46.89%
79.63%
93.34%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
3.26%
27.0%
2.23%
-8.36%
51.45%
Abbott Laboratories
Abbott Laboratories
-2.62%
-2.21%
-0.86%
-5.87%
32.8%
Medtronic Plc
Medtronic Plc
0.44%
2.96%
-1.92%
-33.69%
-13.02%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Tactile Systems Technology I
Tactile Systems Technology I
10.49
10.49
17.24
0.57
0.16
0.04
NA
8.14
Stryker Corporation
Stryker Corporation
38.89
38.89
2.92
11.96
0.19
0.07
0.01
50.33
Boston Scientific Corp.
Boston Scientific Corp.
63.5
63.5
1.8
2.33
0.09
0.05
NA
13.56
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
37.45
37.45
5.19
2.76
0.21
0.12
NA
11.82
Abbott Laboratories
Abbott Laboratories
31.83
31.83
5.99
4.63
0.15
0.06
0.02
22.31
Medtronic Plc
Medtronic Plc
29.48
29.48
1.52
5.2
0.07
0.04
0.03
38.29
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Tactile Systems Technology I
Tactile Systems Technology I
Buy
$306.5M
-74.91%
10.49
10.19%
Stryker Corporation
Stryker Corporation
Buy
$129.9B
82.03%
38.89
16.03%
Boston Scientific Corp.
Boston Scientific Corp.
Buy
$111.1B
93.34%
63.5
12.05%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
Buy
$52.4B
51.45%
37.45
23.01%
Abbott Laboratories
Abbott Laboratories
Buy
$177.8B
32.8%
31.83
13.96%
Medtronic Plc
Medtronic Plc
Buy
$106.7B
-13.02%
29.48
11.36%

Institutional Holdings

  • First Light Asset Management, LLC

    11.12%

  • BlackRock Inc

    9.93%

  • Cadian Capital Management LP

    8.11%

  • Vanguard Group Inc

    5.82%

  • Morgan Stanley - Brokerage Accounts

    3.89%

  • Perceptive Advisors LLC

    3.80%

Company Information

tactile medical is one of the fastest growing companies in medical devices. as a leader in treatment options for lymphedema and venous ulcer therapies, tactile medical develops advanced home therapy devices to improve health and quality of life for patients with chronic swelling . headquartered in minneapolis, minnesota, we advocate for patient access and serve tens of thousands of patients through a direct national network of product specialists and trainers, reimbursement experts, patient advocates, and clinical staff.

Organization
Tactile Systems Technology I
Employees
992
CEO
Mr. Daniel L. Reuvers
Industry
Health Technology

Discover More

FAQs